Osteoporosis

Absolute appendicular lean mass appears to be a suitable marker for predicting osteoporosis based on low muscle mass for postmenopausal women, according to findings published in Menopause.

It will be “many years” before any new pharmacologic osteoporosis therapies are approved, as there are currently no new drugs in phase 2 or 3 development, according to a speaker at the 2021 Congress of Clinical Rheumatology-East meeting.

Researchers found that osteoporosis and fracture were associated with certain lifestyle factors among postmenopausal women, although no factors correlated with an increase in both osteoporosis and fracture.

Just one-third of women older than 65 years were screened for osteoporosis at an internal medicine clinic, and one-third of those diagnosed were untreated, noted a speaker at the 2021 North American Young Rheumatology Investigator Forum.

Patients with rheumatoid arthritis who receive even low daily doses of glucocorticoids are at a 59% increased risk for clinical vertebral fracture, according to data published in Rheumatology.

An above average birth weight is associated with lower bone mineral density and higher fracture risk later in life, according to data published in the Journal of Bone and Mineral Research.

Adults with epilepsy who initiated any osteoporosis drug therapy had a lower 3-year mortality risk compared with those who did not take a medication, according to study data published in Bone.

In this video exclusive, Putting It Into Practice columnist Jonathan D. Leffert, MD, talks with Natalie Cusano, MD, about hyperparathyroidism and osteoporosis.

In this video exclusive, Miguel Regueiro, MD, discussed a presentation from Digestive Disease Week on the impact of biologics on the prevalence of osteoporosis and bone fractures in patients with inflammatory bowel disease.

Postmenopausal women who sustain any type of initial fracture are at a higher risk for a subsequent fracture, according to a study published in EClinicalMedicine.